SCHEMBL5630663

SCHEMBL5630663

O=C1N([C@H]2CC[C@H](O)CC2)CCC12CCN(c1ccc(C(F)(F)F)cn1)CC2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.52
ABL1 P00519 1/20 0.52
LMNA P02545 1/20 0.52
LCAT P04180 5/20 0.47
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HTR7 P34969 1/20 0.45
CXCR3 P49682 2/20 0.45
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KMT2A Q03164 1/20 0.44
HPGD P15428 1/20 0.44
TMEM97 Q5BJF2 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
SCN9A Q15858 1/20 0.44
GPR119 Q8TDV5 1/20 0.43
DPP4 P27487 1/20 0.43
DPP8 Q6V1X1 1/20 0.43
DPP7 Q9UHL4 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5630668 1.00 KDM4E (0.52) KDM4EABL1LMNALCATMAPT
SCHEMBL550342 0.91 KDM4E (0.45) KDM4EABL1LMNALCATMAPT
SCHEMBL549187 0.91 KDM4E (0.45) KDM4EABL1LMNALCATMAPT
SCHEMBL550341 0.91 KDM4E (0.45) KDM4EABL1LMNALCATMAPT
SCHEMBL549371 0.91 KDM4E (0.45) KDM4EABL1LMNALCATMAPT
SCHEMBL549372 0.91 KDM4E (0.45) KDM4EABL1LMNALCATMAPT
SCHEMBL549186 0.91 KDM4E (0.45) KDM4EABL1LMNALCATMAPT
SCHEMBL550855 0.86 KDM4E (0.46) KDM4EABL1LMNAMAPTSMN1; SMN2
SCHEMBL550854 0.86 KDM4E (0.46) KDM4EABL1LMNAMAPTSMN1; SMN2
SCHEMBL17082032 0.86 KDM4E (0.46) KDM4EABL1LMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193207-B2 Lactam compounds and methods of using the same INCYTE CORPORATION (US) 2012-06-05 US claimed
US-20070129345-A1 Lactam compounds and methods of using the same INCYTE CORPORATION 2007-06-07 US claimed
US-8193207-B2 Lactam compounds and methods of using the same INCYTE CORPORATION (US) 2012-06-05 US disclosed
US-8193207-B2 Lactam compounds and methods of using the same INCYTE CORPORATION (US) 2012-06-05 US disclosed
US-8193207-B2 Lactam compounds and methods of using the same INCYTE CORPORATION (US) 2012-06-05 US disclosed
WO-2007067504-A2 LACTAM COMPOUNDS AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2007-06-14 WO disclosed
US-20070129345-A1 Lactam compounds and methods of using the same INCYTE CORPORATION 2007-06-07 US disclosed
US-20070129345-A1 Lactam compounds and methods of using the same INCYTE CORPORATION 2007-06-07 US disclosed
US-20070129345-A1 Lactam compounds and methods of using the same INCYTE CORPORATION 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129345-A1 Lactam compounds and methods of using the same HSD11B1, HSD17B11, HSD17B1 KDM4E 2888/4885ABL1 3984/4885LMNA 2593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.